



# Prior Authorization/Step Therapy Program

This program encourages safe, cost-effective medication use by allowing coverage when certain conditions are met. A clinical team of physicians and pharmacists develops and approves the clinical programs and criteria by reviewing FDA-approved labeling, scientific literature and nationally recognized guidelines.

| Prior Authorization                |   |  |
|------------------------------------|---|--|
| Drug Category                      | Target Drugs  | Program Intent   |
| Accrufer                           | Accrufer  | Helps ensure that there is support for using the agent for the requested indication and age, and that dosing follows what is recommended in product labeling.  |
| Actinic Keratosis                  | <i>Diclofenac Gel: diclofenac gel</i><br><i>Fluorouracil Cream: Carac, Efudex/ fluorouracil cream, Tolak</i><br><i>Imiquimod Cream: Aldara, Zyclara/ imiquimod</i><br><i>Tirbanibulin Ointment: Klisyri</i> | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Acute Migraine                     | Brekiya, Elyxyb, Migranal, Reyvow, Trudhesa   | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| Afrezza                            | Afrezza   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling and encourages appropriate use and the use of cost-effective preferred rapid acting insulin product(s). |
| Agamree Emflaza (formerly Emflaza) | Agamree, Emflaza  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.  |

| Prior Authorization                                     |  |  |
|---|--|--|
| Drug Category   | Target Drugs   | Program Intent   |
| Alhemo  | Alhemo   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Alternative Dosage Form                                 | Carafate/sucralfate suspension, Cuvposa solution, Diphenoxylate-atropine liquid, Entresto sprinkles, Epaned solution, Fleqsuvy suspension, Gimoti/ metoclopramide HCl nasal spray, Indocin suppository, Indocin suspension, Inzirqo suspension, Katerzia suspension, Lopressor oral solution, Lyvispah/ baclofen granules, Meloxicam suspension, Naprosyn/naproxen suspension, Nexium granules, Norliqva/ amlodipine oral solution, Ozobax solution/ baclofen, Qbrelis solution, Sotylize solution, Sprix/ketorolac nasal spray, Tezruly/ terazosin oral solution, Tiglutik suspension | Helps encourage use of the more cost effective oral solid dosage form prior to target agents according to dosing recommended in product labeling. The program requires the prescriber provide documentation that the oral solid dosage form is not clinically appropriate for the patient. This program is not applicable to children, defined as members 12 years of age and under, who often experience issues with being able to swallow oral solid dosage forms. |
| Amifampridine (formerly Firdapse)                       | Firdapse   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Androgens Anabolic Steroids                             | Androgel/generic testosterone, Aveed, Azmiro, Depo-Testosterone, Fortesta, Jatenzo, Kyzatrex, Methitest, Methyltestosterone, Natesto, Testim, Testopel, testosterone enanthate, testosterone solution, Testosterone TD Gel, Tlando, Undecatrex, Vogelxo, Xyosted   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Antifungals (formerly Antifungal Agents)                | Brexafemme, Cresemba, Noxafil/ posaconazole, Tolsura, Vfend/ voriconazole, Vivjoa  | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| Anzupgo   | Anzupgo  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Arikayce  | Arikayce   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| ATTR Amyloidosis (formerly ATTR Amyloidosis Neuropathy) | Attruby, Tegsedi, Vyndaquel, Vyndamax, Wainua  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.  |

## Prior Authorization

| Drug Category  | Target Drugs   | Program Intent  |
|--|--|---|
| Bempedoic Acid   | Nexletol, Nexlizet   | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Biologic Immunomodulators (Rheumatoid Arthritis/Psoriasis) | Abrilada, Actemra subcutaneous, Adalimumab-aacf, Adalimumab-aaty, Adalimumab-adaz, Adalimumab-adbm, Adalimumab-fkjp, Adalimumab-ryvk, Amjevita, Bimzelx, Cimzia, Cosentyx, Cyltezo, Enbrel, Entyvio, Hadlima /adalimumab-bwwd, Hulio, Humira, Humira Starter Kits, Hyrimoz, Idacio, Imuldosa, Kevzara, Kineret, Leqselvi, Litfulo, Olumiant, Omvoh, Orenzia subcutaneous, Otulfi /ustekinumab-aauz, Pyzchiva, Rinvoq, Selarsdi, Siliq, Simlandi, Simponi, Skyrizi, Sotyktu, Starjemza, Stelara, Steqeyma, Taltz, Tremfya, Tyenne, Ustekinumab-aekn, Velsipity, Wezlana, Xeljanz, Xeljanz XR, Yesintek, Yuflyma, Yusimry, Zymfentra | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling. Encourages the use of first-line agents prior to the use of preferred Biological Immunomodulators. Also encourages the use of preferred agents based on indication prior to the use of a non-preferred biologic immunomodulator. |
| Bonjesta/Diclegis  | Bonjesta, Diclegis/doxylamine-pyridoxine   | Helps appropriately select patients for therapy according to product labeling. Accommodates the use of target agents when the prescriber has provided documentation that the use of the individual ingredients within the target combination agent as separate dosage forms is not clinically appropriate.  |
| Brensocatib  | Brensocatib  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| Calcitonin Gene-Related Peptide                            | Aimovig, Ajovy, Emgality, Nurtec ODT, Qulipta, Ubrelvy, Zavzpret   | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Camzyos  | Camzyos  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| Cannabidiol  | Epidiolex  | Helps appropriately select patients for therapy according to product labeling, and/or clinical guidelines and/or clinical studies   |
| Cholestasis Pruritus                                       | Bylvay, Livmarli   | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or clinical guidelines and/or clinical studies.  |

| Prior Authorization  |   |   |
|--|---|---|
| Drug Category  | Target Drugs  | Program Intent  |
| Cibinqo  | Cibinqo   | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Coagulation Factor VIIa  | NovoSeven RT, Sevenfact   | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Combination NSAIDs (Pain Management)   | Duexis/ibuprofen-famotidine, Vimovo/naproxen-esomeprazole, Yosprala/aspirin-omeprazole            | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling. Accommodates the use of target agents when the prescriber has provided documentation that the use of the individual ingredients within the target combination agent as separate dosage forms is not clinically appropriate. |
| Constipation Agents (formerly Opioid Induced Constipation)                     | Amitiza/lubiprostone, Ibsrela, Motegirty/prucalopride, Relistor                                   | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Continuous Glucose Monitor   | Dexcom G6 CGM System, Dexcom G7 CGM System, Freestyle Libre, Freestyle Libre 2, Freestyle Libre 3 | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and according to dosing recommended in product labeling.   |
| Corticotropin (formerly H.P. Acthar)   | Acthar Gel, Cortrophin Gel, Purified Cortrophin Gel   | Helps appropriately select patients for therapy according to product labeling. FDA-approved and/or clinically supported indications limited to infantile spasms for patients under 24 months of age.  |
| Crenessity   | Crenessity  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| Ctexli   | Ctexli  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| Cystic Fibrosis Transmembrane Conductance Regulator (formerly Cystic Fibrosis) | Alyftrek, Kalydeco, Orkambi, Symdeko, Trikafta  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| Daybue   | Daybue  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| Dojolvi  | Dojolvi   | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or clinical guidelines and/or clinical studies.  |

| Prior Authorization   |  |  |
|---|--|--|
| Drug Category   | Target Drugs   | Program Intent   |
| Dry Eye Disease (formerly Ophthalmic Immunomodulators)  | Cequa, Eysuvis, Miebo, Restasis/cyclosporine ophthalmic emulsion, Tryptyr, Tyrvaya, Vevye, Xiidra  | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling. |
| Duvyzat   | Duvyzat  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Efgartigimod  | Vyvgart Hytrulo  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Elagolix Relugolix (formerly Orilissa)  | Myfembree, Oriahnn, Orilissa   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Empaveli  | Empaveli   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Endari (formerly Sickle Cell Disease)   | Endari/L-glutamine   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Enspryng  | Enspryng   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Eohilia   | Eohilia  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Erythropoietins (formerly Erythropoiesis Stimulating Agents (ESAs))   | Aranesp, Epogen, Mircera, Procrit, Retacrit  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies.  |
| Fabhalta  | Fabhalta   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Factor VIII and von Willebrand Factor (formerly Factor VIII and von Willebrand Factor and Hemophilia Factor IX) | Advate, Adynovate, Afstyla, Alphanate, Altuviiio, Elocate, Esperoct, Hemofil M, Humate-P, Jivi, Koâte, Kogenate FS, Kovaltry, NovoEight, Nuwiq, Recombinate, Vonvendi, Wilate, Xyntha, Xyntha Solofuse | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Filspari  | Filspari   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |

| Prior Authorization  |   |  |
|--|---|--|
| Drug Category  | Target Drugs  | Program Intent   |
| Filsuvez   | Filsuvez  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies.  |
| Fintepla   | Fintepla  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Furoscix   | Furoscix  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Galafold (formerly Fabry Disease)  | Galafold  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Gattex (formerly Short Bowel Syndrome)   | Gattex  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies.  |
| GLP-1 (glucagon-like peptide-1) Agonists   | Bydureon Bcise, Byetta, Exenatide, Liraglutide, Mounjaro, Ozempic, Rybelsus, Trulicity, Victoza                                     | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling who have tried an antidiabetic agent.   |
| Growth Hormone (formerly Growth Hormone/Egrifta)   | Genotropin, Humatrope, Norditropin Flexpro, Ngenla, Nutropin AQ, Omnitrope, Saizen, Serostim, Skytrofa, Sogroya, Zomacton, Zorbtive | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies. Idiopathic Short Stature (ISS) is not included in the indications allowed in product labeling.   |
| Harliku  | Harliku   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Hemlibra   | Hemlibra  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Hemophilia Factor IX (formerly Factor VIII and von Willebrand Factor and Hemophilia Factor IX) | AlphaNine SD, Alprolix, BeneFIX, Idelvion, Ixinity, Profilnine SD, Rebinyn, Rixubis   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Hepatitis C Direct Acting Antivirals   | Epclusa, Harvoni, Ledipasvir/Sofosbuvir, Mavyret, Sofosbuvir/Velpatasvir, Sovaldi, Vosevi, Zepatier                                 | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling. Upon meeting criteria, use of the preferred agent by genotype is typically required before non-preferred products in the treatment of Hepatitis C. |
| Hereditary Angioedema  | Andembry, Berinert, Cinryze, Dawnzera, Ekterly, Firazyf/icatibant, Haegarda, Orladeyo, Ruconest, Takhzyro                           | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.  |

## Prior Authorization

| Drug Category  | Target Drugs   | Program Intent   |
|--|--|--|
| Hetlioz  | Hetlioz, Hetlioz LQ  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Hyftor   | Hyftor   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Hympavzi   | Hympavzi   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Hyperhidrosis  | Qbrexza, Sofdra  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Hyperpolarized Activated Cyclic Nucleotide Gated (HCN) Channel Blocker   | Corlanor/ivabradine  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Hypoactive Sexual Desire Disorder  | Addyi, Vyleesi   | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling. |
| Imcivree   | Imcivree   | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.          |
| Insulin Pumps  | iLet Bionic Pancreas, Omnipod Classic Pods, Omnipod DASH Kit Intro, Omnipod DASH pods, Omnipod 5 G6 Kit Intro, Omnipod 5 G6 Pods, Omnipod 5 G7 Kit Intro, Omnipod 5 G7 Pods, twist | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and according to dosing recommended in product labeling.  |
| Interleukin-1 Inhibitors (formerly Inherited Autoinflammatory Disorders) | Arcalyst   | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.          |
| Interleukin-4 Inhibitors (formerly Injectible Atopic Dermatitis Agents)  | Dupixent   | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.          |
| Interleukin-5 Inhibitors   | Fasenra, Nucala  | Helps appropriately select patients for therapy according to product labeling and/or clinical studies and/or compendia and/or guidelines and according to dosing recommended in product labeling.          |

## Prior Authorization

| Drug Category  | Target Drugs  | Program Intent  |
|--|---|---|
| Interleukin-13 Antagonist  | Adbry, Ebglyss  | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| Interleukin-31 Inhibitors  | Nemludio  | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| Interstitial Lung Disease (formerly Idiopathic Pulmonary Fibrosis) | Esbriet, Jascavd, Ofev, pirfenidone   | Helps appropriately select patients for therapy according to product labeling and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Iron Chelation (formerly Deferasirox)                              | Exjade/deferiasirox, Ferriprox, Jadenu/ deferiasirox                            | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| Isturisa   | Isturisa  | Helps appropriately select patients for therapy according to product labeling and/or clinical studies and/or guidelines and according to dosing recommended in product labeling   |
| Joenja   | Joenja  | Helps appropriately select patients for therapy according to product labeling and/or clinical studies and/or guidelines and according to dosing recommended in product labeling.  |
| Jynarque (formerly Polycystic Kidney Disease)                      | Jynarque/tolvaptan  | Helps appropriately select patients for therapy according to product labeling and/or clinical studies and/or guidelines and according to dosing recommended in product labeling   |
| Korlym   | Korlym/mifepristone   | Helps appropriately select patients for therapy according to product labeling and/or clinical studies and/or guidelines and according to dosing recommended in product labeling.  |
| Leqembi  | Leqembi   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| Leucovorin   | Leucovorin  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| Lupus  | Benlysta, Lupkynis  | Helps appropriately select patients for therapy according to product labeling and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Metformin (formerly Metformin ER)                                  | Glumetza/metformin extended-release, Metformin 625 mg, Metformin 750 mg, Riomet | Helps appropriately select patients for therapy according to product labeling and according to dosing recommended in product labeling. Encourage the use of cost-effective non-targeted generic metformin agent over the more expensive brand agents. |

## Prior Authorization

| Drug Category  | Target Drugs  | Program Intent  |
|--|---|---|
| Multiple Sclerosis   | Aubagio, Avonex, Bafiertam, Betaseron, Copaxone, Extavia, Gilenya 0.25 mg, Gilenya 0.50 mg, Kesimpta, Mavenclad, Mayzent, Plegridy, Ponvory, Rebif, Tascenso ODT, Tecfidera, Vumerity | Helps appropriately select patients for therapy according to product labeling and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Myalept  | Myalept   | Helps appropriately select patients for therapy according to product labeling and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Neurotrophic Keratitis                                     | Oxervate  | Helps appropriately select patients for therapy according to product labeling and/or clinical studies and/or guidelines and according to dosing recommended in product labeling.  |
| Niemann-Pick Disease Type C Agents                         | Aqneursa, Miplyffa  | Helps appropriately select patients for therapy according to product labeling and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Northera   | Northera  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| Ohtuvayre  | Ohtuvayre   | Helps appropriately select patients for therapy according to product labeling and/or clinical studies and/or guidelines and according to dosing recommended in product labeling.  |
| Onychomycosis (formerly Antifungal Agents - Onychomycosis) | Ciclopirox, Jublia, Kerydin/tavaborole, Sporanox  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling. Discourages cosmetic utilization.   |
| Opioids  | Oxycontin   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and according to dosing recommended in product labeling.   |
| Opzelura   | Opzelura  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling. Also, to encourage use of Xtampza before use of target products when appropriate. |

## Prior Authorization

| Drug Category   | Target Drugs  | Program Intent   |
|---|---|--|
| Oral Tetracycline Derivatives                                   | <p><i>Doxycycline products:</i> Acticlate/ generic doxycycline, doxycycline monohydrate, capsules 75 mg and 150 mg, Doryx (and generic equivalents), Doryx MPC (and generic equivalents), Doxycycline, doxycycline hyclate tab 50 mg, 75 mg, and 150 mg, Monodox, Oracea, Targadox, Vibramycin</p> <p><i>Minocycline products:</i> Emrosi, Minocin, minocycline tablet 75 mg and 100 mg, Minocycline SR (and generic equivalents), Solodyn (and generic equivalents), Ximino</p> <p><i>Tetracycline products:</i> Seysara, Tetracycline</p> | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and encourages use of preferred oral generic doxycycline and minocycline agents before use of target products when appropriate. |
| Otezla  | Otezla, Otezla XR   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Oxybate (formerly Sodium Oxybate)                               | Lumryz, Sodium Oxybate, Xyrem, Xywav  | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Pancreatic Enzymes  | Creon, Pancreaze, Pertzye, Viokace, Zenpep  | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| Parathyroid Hormone Analog Osteoporosis (formerly Osteoporosis) | Bonsity, Forteo, Teriparatide, teriparatide, Tymlos   | Helps appropriately select patients for therapy according to product labeling and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| PCSK9 Inhibitors  | Praluent, Repatha   | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| Peg-interferon  | Pegasys   | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Phenylketonuria (formerly Enzyme Deficiency)                    | Javygtor, Kuvan/sapropterin, Palyntiq, Sephience  | Helps appropriately select patients for therapy according to product labeling and/or guidelines and/or clinical studies.   |
| Primary Biliary Cholangitis (formerly Ocaliva)                  | Iqirvo, Livdelzi, Ocaliva   | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.  |

| Prior Authorization   |  |   |
|---|--|---|
| Drug Category   | Target Drugs   | Program Intent  |
| Procysbi  | Procysbi   | Helps appropriately select patients for therapy according to product labeling and/or guidelines and/or clinical studies.  |
| Pseudobulbar Affect   | Nuedexta   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling. |
| Pulmonary Arterial Hypertension (formerly Oral Pulmonary Hypertension Agents) | Adcirca/tadalafil, Adempas, Alyq, Letairis/ambrisentan, Liqrev, Opsumit, Opsynvi, Orenitram, Revatio, Sildenafil suspension, Tadliq, Tracleer/bosentan, Tyvaso, Uptravi, Ventavis, Winrevair, Yutrepia | Helps appropriately select patients for therapy according to product labeling and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.          |
| Pyrukynd  | Pyrukynd   | Helps appropriately select patients for therapy according to product labeling and/or clinical studies and/or guidelines and according to dosing recommended in product labeling.          |
| Qfitlia   | Qfitlia  | Helps appropriately select patients for therapy according to product labeling and/or clinical studies and/or guidelines and according to dosing recommended in product labeling.          |
| Radicava  | Radicava ORS   | Helps appropriately select patients for therapy according to product labeling and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.          |
| Rapid to Intermediate Acting Insulin (formerly Insulin Agents)                | Admelog, Admelog Solostar, Apidra, Fiasp pumpcart, Insulin Aspart, Insulin Aspart Mix, Insulin Lispro, Insulin Lispro Junior Kwikpen, Insulin Lispro Kwikpen, Insulin Lispro Mix, Kirsty, Merilog      | Encourages the use of preferred insulin products unless not clinically appropriate and that dosing follows what is recommended in product labeling.                                       |
| Rayos   | Rayos  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling. |
| Recorlev  | Recorlev   | Helps appropriately select patients for therapy according to product labeling and/or clinical studies and/or guidelines and according to dosing recommended in product labeling.          |
| Resmetirom  | Rezdiffra  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling. |
| Rezurock  | Rezurock   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling. |
| Rhapsido  | Rhapsido   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling. |

## Prior Authorization

| Drug Category                       | Target Drugs  | Program Intent  |
|-------------------------------------|---|---|
| Risdiplam                           | Evrysdi   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.         |
| Rivfloza                            | Rivfloza  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.         |
| Selective Serotonin Inverse Agonist | Nuplazid  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.         |
| Self-administered Oncology          | Afinitor/everolimus, Afinitor Disperz, Akeega, Alecensa, Alunbrig, Augtyro, Avmapki Fakzynja Co-Pack, Ayvakit, Balversa, Besremi, Bosulif, Braftovi, Brukinsa, Cabometyx, Calquence, Caprelsa, Cometriq, Copiktra, Cotellic, Danziten, Daurismo, Ensacove, Erivedge, Erleada, Farydak, Fotivda, Fruzaqla, Gavreto, Gilotrif, Gleevec/imatinib, Gomekli, Hernexeos, Hycamtin, Hyrnuo, Ibrance, Ibtrozi, Iclusig, Idhifa, Imbruvica, Imkeldi, Inluriyo, Inlyta, Inqovi, Inrebic, Iressa, Itovebi, Iwilfin, Jakafi, Jaypirca, Krazati, Kisqali, Kisqali Femara Pack, Komzifti, Koselugo, Lazcluze, Lenvima, Lonsurf, Lorbrena, Lumakras, Lynparza, Lysodren, Lytgobi, Matulane, Mekinist, Mektovi, Modeyso, Nerlynx, Nexavar, Nilotinib d-tartrate, Ninlaro, Nubeqa, Odomzo, Ogsiveo, Ojjaara, Onureg, Orgovyx, Orserdu, Pemazyre, Phyrago, Piqray, Pomalyst, Qinlock, Retevmo, Revlimid/lenalidomide, Revuforj, Rezlidhia, Romvimza, Rozlytrek, Rubraca, Rydapt, Scemblix, Sprycel, Stivarga, Sutent/sunitinib, Tabrecta, Tafinlar, Tagrisso, Talzena, Tarceva/erlotinib, Targretin/bexarotene, Tassigna/nilotinib, Tazverik, Temodar/temozolomide, Tepmetko, Thalamid, Tibsovo, Tretinoin, Truqap, Tukysa, Turalio, Tykerb/lapatinib, Vanflyta, Venclexta, Verzenio, Vitrakvi, Vizimpro, Vonjo, Voranigo, Votrient/paznopanib, Welirug, Xalkori, Xeloda, Xospata, Xpovio, Xtandi, Yonsa, Zelboraf, Zolanza, Zydelig, Zykadia, Zytiga/abiraterone | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or guidelines and/or clinical studies and according to dosing recommended in product labeling. |

| Prior Authorization                             |   |   |
|---|---|---|
| Drug Category                                   | Target Drugs                            | Program Intent  |
| Skyclarys                                       | Skyclarys                               | Helps appropriately select patients for therapy according to product labeling and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Sohonos   | Sohonos                                 | Helps appropriately select patients for therapy according to product labeling and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Somatostatin (formerly Somatostatin Analogs)    | Bynfezia, Mycapssa, Palsonify, Somavert | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| Spevigo   | Spevigo                                 | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| Strensiq  | Strensiq                                | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or guidelines and/or clinical studies.   |
| Substrate Reduction Therapy (formerly Cerdelga) | Cerdelga, Opfolda, Zavesca/miglustat    | Helps appropriately select patients for therapy according to product labeling and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Sucraid   | Sucraid                                 | Helps appropriately select patients for therapy according to product labeling and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Sunosi  | Sunosi                                  | Helps appropriately select patients for therapy according to product labeling and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Supplemental Therapeutic Alternatives           | Daraprim, Rytary                        | Helps appropriately select patients for therapy according to product labeling and according to dosing recommended in product labeling and helps ensure the appropriate use of cost-effective, clinically appropriate, preferred alternatives over other high-cost agents. |
| Tarpeyo   | Tarpeyo                                 | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| Tavneos   | Tavneos                                 | Helps appropriately select patients for therapy according to product labeling and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.  |
| Tezspire  | Tezspire                                | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.   |

## Prior Authorization

| Drug Category  | Target Drugs  | Program Intent  |
|--|---|---|
| Therapeutic Alternatives   | Absorica, Absorica LD, Adapalene, Ala-Scalp, Alphagan-P, Amrix, Aplenzin, Ativan, Azelex, Bethkis, Bucapsol, Bupap, Cabtreo, Cafergot, Cambia/diclofenac, Carbinoxamine Maleate 6mg, Chlorzoxazone, Coxanto, Crotan Lotion, Cuprimine, Denavir Cream 1%, diclofenac potassium, Diflorasone cream, diflorasone ointment, Econazole Nitrate 1% foam, Elepsia XR, Ergomar, Ertaczo 2% cream, Exelderm 1% cream, Exelderm 1% solution, Extina, Fenoprofen, fenofibrate 120 mg, Flurazepam, Innopran XL, Kenalog spray, Ketoprofen 25 mg, Ketoprofen 50 mg, Ketoprofen ER 200 mg, Kitabis Pak, Konvomep suspension, Lexette, Librax, Lorzone, mefenamic acid, Metaxalone 640 mg, mupirocin cream, naftifine 1% cream, Naftin 2% cream, Naftin 1% gel, Naftin 2% gel, Nalfon, Nalocet, Naprelan, Neffy, Noritate, Onexton, Oxistat, prednisolone sodium phosphate solution, prednisolone tablet, Prolate, Reltone, Rhofade, Sitavig, Sorilux, Sovuna, Tanlor, TOBI, TOBI Podhaler, Treximet 85/500 mg, Vivlodex, Wellbutrin XL, Xerese, Zegerid/omeprazole-sodium bicarbonate, Zembrace, Zipsor, Zovirax cream 5% | Helps appropriately select patients for therapy according to product labeling and according to dosing recommended in product labeling and helps ensure the appropriate use of cost-effective, clinically appropriate, preferred alternatives over other high-cost agents. |
| Thrombopoietin Receptor Agonists, Tavalisse, and Wayrilz (formerly Thrombopoietin Receptor Agonists and Tavalisse) | Alvaiz, Doptelet, Mulpleta, Nplate, Promacta/eltrombopag, Tavalisse, Wayrilz  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| Topical Doxepin  | Doxepin, Prudoxin, Zonalon cream  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.   |
| Topical Lidocaine  | Lidoderm/lidocaine patch, lidocaine ointment, Pliaglis, Ztlido  | Encourages the use of OTC topical lidocaine products unless not clinically appropriate and that dosing follows what is recommended in product labeling.   |
| Topiramate ER  | Qudexy XR/Topiramate ER, Trokendi XR  | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.   |

| Prior Authorization  |   |  |
|--|---|--|
| Drug Category  | Target Drugs  | Program Intent   |
| Tryngolza  | Tryngolza   | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.          |
| Tryvio   | Tryvio  | Helps appropriately select patients for therapy according to product labeling and/or guidelines and/or clinical studies and according to dosing recommended in product labeling.                           |
| Urea Cycle Disorders   | Buphenyl/sodium phenylbutyrate, Olpruva, Pheburane, Ravicti/glycerol phenylbutyrate | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or clinical guidelines and/or clinical studies.   |
| Vanrafia   | Vanrafia  | Helps appropriately select patients for treatment according to product labeling and/or clinical studies and/or guidelines and according to dosing recommended in product labeling.                         |
| Vascepa  | Vascepa/icosapent ethyl   | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling. |
| Vasomotor Symptoms (formerly Neurokinin Receptor Antagonists)        | Lynkuet, Veozah   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Verkazia   | Verkazia  | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling. |
| Verquvo  | Verquvo   | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling. |
| Vijoice  | Vijoice   | Helps appropriately select patients for treatment according to product labeling and/or clinical studies and/or guidelines and according to dosing recommended in product labeling.                         |
| VMAT2 Inhibitors (formerly Huntington's Disease/Tardrive Dyskinesia) | Austedo, Austedo XR, Ingrezza, Xenazine/tetrabenazine                               | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling. |
| Vowst  | Vowst   | Helps appropriately select patients for treatment according to product labeling and/or clinical studies and/or guidelines and according to dosing recommended in product labeling.                         |
| Voxzogo  | Voxzogo   | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |

## Prior Authorization

| Drug Category | Target Drugs     | Program Intent   |
|---------------|------------------|--|
| Voydeya       | Voydeya          | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Vtama         | Vtama            | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies.  |
| Vyjuvek       | Vyjuvek          | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Vykat XR      | Vykat XR         | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Wakix         | Wakix            | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Winlevi       | Winlevi 1% cream | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies.  |
| Xdemvy        | Xdemvy           | Helps appropriately select patients for therapy according to product labeling and/or compendia and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling. |
| Xhance        | Xhance           | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Xolair        | Xolair           | Helps appropriately select patients for treatment according to product labeling and/or compendia and/or clinical studies and/or guidelines and according to dosing recommended in product labeling.        |
| Xolremdi      | Xolremdi         | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Xphozah       | Xphozah          | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Yorvipath     | Yorvipath        | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |
| Zelsuvmi      | Zelsuvmi         | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.                  |

## Prior Authorization

| Drug Category | Target Drugs | Program Intent  |
|---------------|--------------|---|
| Zeposia       | Zeposia      | Helps appropriately select patients for treatment according to product labeling and/or compendia and/or clinical studies and/or guidelines and according to dosing recommended in product labeling. |
| Zilbrysq      | Zilbrysq     | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies and according to dosing recommended in product labeling.           |
| Zokinvy       | Zokinvy      | Helps appropriately select patients for treatment according to product labeling and/or clinical studies and/or guidelines and according to dosing recommended in product labeling.                  |
| Zoryve        | Zoryve       | Helps appropriately select patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies.   |

## Step Therapy

| Drug Category                     | Target Drugs   | Program Intent   |
|-----------------------------------|--|--|
| Antidepressants                   | Auvelity, Bupropion ER 450 mg, Celexa, Citalopram, Cymbalta, desvenlafaxine ER tabs, Drizalma Sprinkle, Effexor, Effexor XR, Escitalopram, Exxua, Fetzima, fluoxetine 60 mg tabs, Fluoxetine delayed release, Forfivo XL, Lexapro, Paxil, Paxil CR, Pexeva, Pristiq, Prozac, Remeron, Remeron SolTab, Sertraline, Trintellix, Venlafaxine ER, Viibryd, Wellbutrin SR, Zoloft | Encourages the use of preferred generic antidepressants for patients with new prescriptions for brand agents unless not clinically appropriate, according to dosing recommended in product labeling. When prescribed for neuropathic pain or fibromyalgia or musculoskeletal pain, encourages use of first-line generic agents before Cymbalta unless not clinically appropriate, according to dosing recommended in product labeling. |
| Atopic Dermatitis                 | Elidel/pimecrolimus, Eucrisa, tacrolimus   | Encourages the use of topical corticosteroid or topical corticosteroid combination preparations prior to, or concurrent with, Elidel, Eucrisa, or Protopic/tacrolimus unless not clinically appropriate  |
| Atypical Antipsychotics           | Abilify, Clozaril, Cobenfy, Fanapt, Geodon, Invega, Latuda, Lybalvi, Opipza, Risperdal, Risperidone ODT, Saphris, Secuado, Seroquel, Seroquel XR, Versacloz, Zyprexa, Zyprexa Zydis  | Encourages the use of cost-effective generic atypical antipsychotic agents over brand atypical antipsychotic agents unless not clinically appropriate, according to dosing recommended in product labeling.  |
| Colony Stimulating Factors        | Fylnetra, Granix, Neupogen, Nypozi, Nyvepria, Releuko, Rolvedon, Ryzneuta, Stimufend, Udenyca, Ziextenzo   | Encourage the use of formulary agent prior to the use of non-formulary agents, unless not clinically appropriate   |
| DPP-4 Inhibitors and Combinations | Alogliptin, Alogliptin-metformin, Alogliptin-pioglitazone, Brynovin, Jentadueto, Jentadueto XR, Kombiglyze XR, Nesina, Onglyza, Sitagliptin, Sitagliptin-metformin, Sitagliptin-metformin ER, Tradjenta, Zituvio, Zituvimet, Zituvimet XR  | Encourages the use of preferred agent before the nonpreferred products unless not clinically appropriate, according to dosing recommended in product labeling.   |

| Step Therapy  |   |  |
|---|---|--|
| Drug Category   | Target Drugs  | Program Intent   |
| Gabapentin ER   | Gralise/gabapentin, Horizant  | Encourages use of cost-effective generic immediate release gabapentin agent prior to use of ER product unless not clinically appropriate, according to dosing recommended in product labeling.   |
| Glucose Test Strips   | All non-preferred brand test strips and disks   | Encourages the use of preferred glucose test strip products before the nonpreferred products, unless not clinically appropriate, according to dosing recommended in product labeling.  |
| Infertility <sup>1</sup>  | Chorionic Gonadotropin, Gonal F, Gonal F RFF, Novarel   | Encourages the use of formulary agent prior to the use of the non-formulary agents unless not clinically appropriate, according to dosing recommended in product labeling.   |
| Insomnia  | Ambien, Ambien CR, Belsomra, Dayvigo, Edluar, Lunesta, Quviviq, Rozerem, Silenor, Zolpidem                  | Encourages the use of cost-effective generic insomnia agents over brand agents. Also, accommodates use of brand nonbenzodiazepine hypnotics (i.e., Ambien, Ambien CR, Belsomra, Dayvigo, Edluar, Lunesta, Quviviq, and Zolpimist); Rozerem; and Silenor when generic agents cannot be used unless not clinically appropriate, according to dosing recommended in product labeling. |
| Kerendia  | Kerendia  | Encourages the use of an antidiabetic or ACE/ARB, before Kerendia, unless not clinically appropriate, per clinical guidelines.   |
| Ophthalmic Prostaglandins (formerly Glaucoma)   | Iyuzeh, Lumigan, Omlonti, Travatan Z, Vyzulta, Xalatan, Xelpros, Zioptan                                    | Encourage the use of a cost-effective generic ophthalmic prostaglandin unless not clinically appropriate, according to dosing recommended in product labeling.   |
| Oral Inhalers   | Advair Diskus, Alvesco, Fluticasone furoate ellipta, Fluticasone propionate aerosol inhalation              | Encourage the use of formulary agent prior to the use of non-formulary agents, unless not clinically appropriate, according to dosing recommended in product labeling.   |
| Phosphate Binder  | Auryxia, Fosrenol/lanthanum carbonate, Renagel, Renvela, Velphoro   | Encourage the appropriate use of cost-effective generic phosphate binder agents over brand agents unless not clinically appropriate.   |
| SGLT Inhibitors (formerly Sodium-glucose Co-transporter (SGLT) Inhibitors and Combinations) | Brenzavvy/Bexagliflozin, Inpefa, Invokana, Invokamet, Invokamet XR, Qtern, Segluromet, Steglatro, Steglujan | Encourage the use of formulary agent prior to the use of non-formulary agent, unless not clinically appropriate, according to dosing recommended in product labeling.  |
| Topical NSAIDs (formerly Topical Non-Steroidal Anti-Inflammatory Drug)                      | Flector, Licart, Pennsaid/diclofenac 2% solution  | Encourage the use of cost-effective OTC or generic prescription oral non-steroidal anti-inflammatory drug (NSAID) products, unless not clinically appropriate, according to dosing recommended in product labeling.  |

These programs are included in the standard utilization management package and apply for some standard pharmacy benefit plans. Not all drug categories are included in all plans, based on the member's drug list, and some plans have additional categories not listed. Refer to the member's benefit materials or call the phone number on the member's Blue Cross and Blue Shield of Montana ID card to determine whether a particular category is part of the member's benefit. This list is subject to change without notice. Call 800-285-9426 to confirm the status of a particular drug.

<sup>1</sup> The infertility step therapy program does not apply for standard HMO plans.

Third-party brand names are the property of their respective owners.